FDA Approves Medicine for Women with Platinum-Sensitive Recurrent Ovarian Cancer
December 6th, 2016
On December 6, the FDA approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
News in brief
- Avastin plus chemotherapy for platinum-sensitive recurrent ovarian cancer approved today based on results from two large Phase III studies, GOG-0213 and OCEANS
- Ovarian cancer causes more deaths than any other gynecologic cancer in the United States1
- Women are said to have a ‘platinum-sensitive’ form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy 2
- In the United States, Avastin is now approved for nine distinct uses across six different types of cancer
Supporting Information
"This approval was based in part on a Gynecologic Oncology Group cooperative clinical trial and reinforces the importance of partnerships with study groups to identify new treatment options for people in need.”